Fat-cell injection shrinks harmful belly fat in phase 2 study

Clinical takeaway: A novel injectable agent, CBL-514, reduced MRI-measured visceral adipose tissue (VAT) as well as subcutaneous fat in a phase 2 trial, raising the possibility of a new obesity treatment strategy that directly eliminates fat cells. However, metabolic outcomes and long-term clinical benefits remain unproven.

Most obesity drugs work by suppressing appetite or altering metabolism, but they do not directly reduce the number of fat cells. Visceral fat, which surrounds abdominal organs, is strongly linked to insulin resistance, type 2 diabetes, and cardiovascular disease, making it an attractive therapeutic target. Findings were presented at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting and have not yet been peer reviewed.

CBL-514 is a first-in-class injectable small molecule designed to selectively trigger apoptosis in adipocytes while sparing other cell types. Investigators analyzed MRI data from a subgroup of participants enrolled in two phase 2 studies. The analysis included 23 participants receiving CBL-514 and 17 receiving placebo, all with BMI values of 22-30 kg/m².

At 4 weeks after treatment, visceral fat volume fell by about 12% in the CBL-514 group but increased nearly 6% with placebo, creating a roughly 18-percentage-point difference between groups. At the final follow-up, conducted 8-12 weeks after the last injection, visceral fat remained about 10% below baseline with CBL-514 while increasing nearly 12% with placebo, a more than 22-percentage-point separation. Average VAT volume decreased by approximately 63-71 mL with active treatment and increased by 31-78 mL with placebo.

The drug was generally well tolerated, with mostly mild-to-moderate injection-site reactions such as pain, swelling, and redness, and no serious adverse events reported. Supporting animal studies also suggested that combining CBL-514 with tirzepatide produced greater visceral-fat reduction and less weight regain after tirzepatide discontinuation than tirzepatide alone.

“This is a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results in early human trials,” said study author W. Timothy Garvey, MD.

Source: Ling YF, et al. (2026 Oct 2) EASD Annual Meeting 2026, late-breaking abstract LBA57. CBL-514, a First-in-Class Adipocyte Apoptosis-Inducing Injection, Reduces MRI-Measured L2-L3 Visceral Adipose Tissue: Translational Evidence from Preclinical Models to a Phase 2 Clinical Trial